American Journal of Biomedicine and Pharmacy
https://biojournals.us/index.php/AJBP
ISSN: 2997-7177

Design and Synthesis of New Pharmaceutical Compounds as Potent A-Glucosidase Inhibitors and their Role in the Treatment of Type II Diabetes Mellitus

Ola Hussein Noor Abd
University of Al - Qadislyah College of Science Department of Chemistry

Noor Kazim Hashim Kazim
Al-Qadisiyah University College of Science Department of Chemistry

Laith Aziz Jebur Hussein, Mosadeq Ameer Hasson Hamza
University of Al-Qadisiyah College of Science Department of Chemistry

Received: 2024, 15, Aug
Accepted: 2025, 21, Sep
Published: 2025, 31, Oct

Annotation: Despite many effective treatments, Type II Diabetes (T2D) remains a critical health issue, affecting hundreds of millions globally. The well-established T2D treatment strategy of inhibiting α-glucosidase—the critical enzyme in carbohydrate metabolism—offers new opportunities to advance therapeutic options. A rational design strategy targeting α-glucosidase has been established, and new inhibitors with improved potency, selectivity, and bioavailability have been designed and synthesized . With anticipated oral bioavailability and sustained postprandial control, these compounds exhibit strong translational potential for supporting T2D management.

Approximately 542 million adults are currently living with diabetes, with elevated blood glucose levels being the central common denominator for this epidemic. These distressing figures are continuing to rise at alarming rates across the globe, with Type 2 Diabetes (T2D) accounting for a staggering 90% of all the cases. The burden that this condition places on human

health, as well as on healthcare systems worldwide, is truly staggering, and growing more severe with time. Despite this, the discovered approaches for its effective management—including the inhibition of α-glucosidase—remain indispensable and critically important. The extensive exploration of α-glucosidase inhibitors has yielded only modest progress in drug development, which highlights the ongoing need for novel therapeutic candidates in this area. Indeed, multiple agents aimed at targeting α-glucosidase are extensively used around the world, and thus they constitute a subject of notable research attention and focus among healthcare professionals and researchers alike.

1. Introduction to Type II Diabetes and α-Glucosidase

Diabetes is one of the most prevalent metabolic diseases worldwide. Due to a high glycemic index, it leads to an upsurge of postprandial blood glucose levels in patients. The postprandial rise in blood glucose occurs due to starch hydrolysis in the digestive system. α-Glucosidase inhibitors block starch hydrolysis at the intestinal level, which helps in the diabetic management of patients. α-Glucosidase is considered an important target for the management of type II diabetes. A flexible, efficient, and inexpensive Schmidt reaction has been developed for the synthesis of 2-aryl-5-(1H-1,2,4-triazol-3-yl)-1H-phenyl-1-ones and Synthesis of new diphenyl urea-clubbed imine analogs having α-glucosidase inhibitory activity has been focused on through in vitro and in silico approaches. A cascade reaction for the preparation of 1-benzyl-5-aryl-1H-pyrrole-2-carbaldehydes can be achieve from readily available isocyanides, which are new colorimetric chemosensors has been reported. Several benzo-fused five-membered heterocycles containing an isoniazid moiety have been synthesized through an iterative approach. In vitro evaluation of the anticancer activity for the prepared compounds against •A549, a non-small cell lung cancer, and•HepG2, a liver cancer cell line has been carried out. In-silico molecular docking studies performed on protein 1MZQ revealed the binding affinity of the compounds. Compounds [4i, 6a, 7e, and 7h] showed promising anticancer activity against the selected cell lines [1].

1.1. Pathophysiology of Type II Diabetes

Diabetes mellitus (DM) comprises a group of chronic metabolic diseases characterized by hyperglycemia caused by insulin insufficiency or reduced insulin sensitivity and resulting in fatty acid, carbohydrate, and protein metabolism disruption. Prolonged hyperglycemia is a main reason for different complications and premature death and gives rise to significant challenges with obesity, excessive urination, thirst, marked appetite increase, blindness, and many other cardiovascular, renal, and neurodegenerative diseases [2]. Type 2 diabetes (T2DM), the most prevalent form of the disease, constitutes ≈90% of diagnosed cases across both adult and even younger populations due to a poor dietary regimen, lack of physical exercise, and increasing obesity. The available transformation therapy relies primarily on anti-diabetic agents such as α-glucosidase inhibitors; a certain drug (acarbose) meddles with carbohydrate-decomposition enzymes to achieve satisfying reduction of post-prandial hyperglycemia; however, the extensive long-term employment is accompanied by unwanted effects such as diarrhea and nausea.

Therefore, the pursuing of new alternative α-glucosidase inhibitors remains highly desirable. Among a broad category of benzimidazole compounds, several derivatives have recently emerged as promising therapeutic entities, exhibiting, for example, potent α-glucosidase inhibition besides other activities. A novel exploration of the benzimidazole-Schiff base construct toward new inhibitors with improved activity holds certain validity [3].

1.2. Role of α-Glucosidase in Carbohydrate Metabolism

Carbohydrates are polysaccharide macromolecules that yield monosaccharides either during digestion or via enzymatic hydrolysis. The α-glucosidase enzyme, found primarily in the intestine, initiates carbohydrate digestion following gastric activity by hydrolyzing at the 1-2 or 1-4 bond locations of maltose, maltotriose, isomaltose, and oligosaccharides. Inhibiting α-glucosidase serves as the therapy's substantive mechanism: it slows glucose absorption from the intestinal tract into the bloodstream after meals, thereby reducing postprandial glucose peaks that would lead to long-term hyperglycemia [4].

Figure 1 presents a simplified map of carbohydrate digestion. Food enters the stomach after mastication, where acidic gastric secretion disassembles polysaccharides. The subsequent small-intestinal phase introduces pancreatic amylase to complete hydrolysis to oligosaccharides, followed by α-glucosidase-mediated hydrolysis to free glucose [1]. The left and right panels illustrate normal digestion and digestion inhibited by α-glucosidase inhibitors, respectively. Inhibition suppresses glucose release, leading to lower blood concentration and milder hyperglycemia [5].

2. Pharmacology of α-Glucosidase Inhibitors

α-Glucosidase inhibitors, such as acarbose and miglitol, control postprandial glucose excursions by delaying the intestinal absorption of carbohydrates. These inhibitors slow the transformation of poly- and oligosaccharides into monosaccharides in the small intestine, effectively reducing glucose absorption. The therapeutic rationale rests on the understanding that many Type II Diabetes patients predominantly suffer from postprandial hyperglycemia [1]. The desired physiological exposure-response relationship is therefore low systemic exposure, coupled with modest, well-timed dosing concomitant with meals. Such principles must guide new compound design to significantly curb postprandial peaks, pyruvate accumulation, and downstream de novo lipogenesis and glucagon production [3]. Systemic activity beyond α-glucosidase inhibition is also critical to maintain translational potential and avoid reliance on narrow therapeutic windows.

Inhibitors can be classified as either competitive or uncompetitive. The former bind reversibly to the free enzyme, with a typical IC50 around 1 μM. Uncompetitive inhibitors bind to the enzyme-substrate complex, producing a parallel effect on Vmax and Km; IC50 values range from 20–400 nM. For competitive inhibitors, the precise amino acid interactions and overall binding mode within the enzyme active site depend on the chemical structure. Structures that improve the binding affinity and restrict rotation can be readily explored through diverse structural motifs; a knowledge-rich concept map outlines these relationships. [6][7][8]

2.1. Mechanism of Action and Therapeutic Rationale

The α-glucosidase inhibitors acarbose, miglitol, and voglibose prove effective for controlling postprandial glycemic excursions in Type II Diabetes patients, yet significant adverse effects limit their clinical utility. Hence, potent, safe alternatives remain an area of active investigation. Carbohydrate digestion entails the sequential breakdown of starch and oligosaccharides into broadly absorbed monosaccharides, a process regulated by α-amylase and α-glucosidase [9]. Starch digestion predominantly occurs in the stomach, while oligosaccharide hydrolysis is more extensive in the intestinal cavity and mucosa. Since insulin-independent mechanisms regulate postprandial glucose clearance, critically elevated glycemic peaks can arise from excessive absorption downstream of the α-amylase action. α-Glucosidase thus plays a key role in

carbohydrate metabolism, and its competitive or uncompetitive inhibition immediately downstream of α-amylase represents a rationale therapeutic intervention.

Acarbose and related inhibitors achieve α-glucosidase inhibition through either competitive or uncompetitive modes [10]. Competitive inhibitors, which bind the enzyme active site and directly compete with substrates, typically exhibit submicromolar to low-micromolar IC50 values. Uncompetitive inhibitors require substrate-bound α-glucosidase for binding and show micromolar to low-millimolar IC50 values. Both α-glucosidase and α-amylase facilititate polysaccharide glucosidic linkage hydrolysis, generating various oligosaccharides—substrates for α-glucosidase. Despite the structural diversity of oligosaccharides released from α-amylase activity on starch, starch itself has limited dietary sources. The variability of uncompetitive inhibitor IC50 values against starch and the limited physiological supply of starch-derived oligosaccharides further substantiates competitive inhibition as a more favorable design strategy.

Despite these insights, established α-glucosidase inhibitors fail to satisfy potency, postprandial glucose peak reduction, and meal-length coupling simultaneously. Consequently, greater inhibitory potency remains paramount to enhancing their therapeutic profile and would permit alternative meal-composition coupling strategies.

2.2. Pharmacokinetics and Pharmacodynamics

Inhibition of α-glucosidase is a well-characterized therapeutic strategy for controlling carbohydrate metabolism and, by extension, postprandial glucose levels in Type II Diabetes mellitus [11]. Extracellular α-glucosidase inhibitors reduce glucose absorption through competitive or uncompetitive mechanisms; their half-maximal inhibitory concentrations (IC50) are typically in the submicromolar range; and their activity is influenced by meal composition [12]. The efficacy of α-glucosidase inhibitors is therefore greatly affected by their pharmacokinetic properties, exposure-response relationships, and tissue bioavailability. For the designed compounds, selection criteria emphasize retention of a metabolic labile site that limits parenteral absorption and extends the duration of action.

α-Glucosidases are membrane-associated enzymes that hydrolyze α-glucosidic linkages within oligosaccharides, polysaccharides, and glycoproteins. They are classified as glycoside hydrolases and have been assigned to family 31 of the CAZy classification scheme. Following gastric digestion, α-glucosidase plays a key role in the small-intestinal degradation of maltotriose, maltotetraose, and oligosaccharides remaining from starch digestion; a further peak in glucose concentration within 30–120 minutes postmeal can therefore be expected when starches enter the diet. Compounds with suitable cyclic and open-chain block structures were therefore targeted; microwave-assisted synthetic protocols enabled rapid access to candidate libraries for preliming biological profiling. [13][14][15]

3. Chemistry and Design Principles

Compounds designed to engage α-glucosidase in the active site limit postprandial glucose excursions by controlling small intestinal digestion of dietary carbohydrates. Structure-activity relationships (SARs) for new candidates rely on established scaffolds known to operate through competitive or uncompetitive inhibition with low micromolar IC50 values. Based on SAR insights, targeted structural motifs can be introduced via practical synthetic routes to balance potency and bioavailability.

Selective and broadly applicable synthetic methods allow access to an extensive collection of new α-glucosidase inhibitors. Synthesis of enantiomerically pure candidates employs readily available intermediates via scalable routes. Established transformations and commercially available reagents provide straightforward pathways to introduce targeted structural motifs, consistent with remaining compound design principles. Simple modifications shape compound profiles and moderate drug-like properties.

A systematic drive to optimize candidate compounds for potent, selective α-glucosidase inhibition targets Type II diabetes therapy. Iterative substitutions and deletions inform the selection of new designs aimed at improved target engagement. Clarity of structure-activity relationships (SARs) for candidate compounds facilitates exploration of design modifications expected to enhance activity, lead to desirable exposure-time profiles, and influence downstream pharmacokinetics. [16]

3.1. Structural Motifs Known for Inhibition

α-Glucosidase inhibitors are a diverse class of compounds, which exhibit varying modes of action and are either derived from natural products or designed as small synthetic molecules. Several scaffolds have been shown to possess α-glucosidase inhibitory activity, and large structural diversity has been reported.

The saturated polyhydroxylated cyclic sugar moieties are potent α-glucosidase inhibitors. The post-translational modifications of some amino acids are known to be critical for α-glucosidase activity. Several natural products, which are glycosylated derivatives of flavonoids and isoflavones, inhibit the enzyme. Besides polyhydroxy benzenoids, compounds exhibiting inhibitory activity in the low micromolar range are heterocycles that can form hydrogen bond interactions with the active site residues involved in the catalytic mechanism. Synthetic inhibitors that mimic the transition-state structure for glycosidic hydrolysis and/or bind to additional sites in the enzyme are promising because of their reported low toxicity and relative stability. In addition to small molecular weight compounds, indoleamine 2,3-dioxygenase inhibitors and polyphenols have been reported to be more selective toward the endoplasmic reticular isoforms. [17][18]

3.2. Rational Drug Design Strategies

Scaffold-hopping, bioisosterism, and intuitive optimization serve as primary guiding strategies in the rational design of new α-glucosidase inhibitors. The inherent presence of chemical motifs already known to engage with the target allows for rapid benchmarking of new candidates against existing agents under consideration for synthesis [1]. In particular, focus on fit with the active site rather than the size of the overall structure encourages the exploration of diverse scaffolds and the discovery of new, potentially more potent antiviral classes [10]. Bioisosterism provides another versatile strategy to facilitate structural variability while controlling fundamental physicochemical properties. For example, α,β-unsaturated carbonyl moieties and non-conjugated carbonyl compounds retain a similar acceptor-donor arrangement and HB character, enabling retention of interatomic-contact patterns critical for target engagement [12]. Candidate inhibitors other than the original acarbose continue to target α-glucosidase primarily to reduce post-prandial glucose spikes; thus, optimization proceeds along four complementary design goals: (1) enhanced target binding, (2) greater human biocompatibility, (3) manageable pharmacokinetic profiles, and (4) multidimensional freedom for ongoing structural improvement.

3.3. Computational Approaches in Inhibitor Design

Molecular docking, quantitative structure-activity relationship (QSAR) studies, and molecular dynamics have been successfully applied for the selection of a new series of α-glucosidase inhibitors. The binding mode of the different classes of inhibitors has been studied against the 3D crystallographic structure of the enzyme (PDB ID: 2Q1J) using molecular docking. Based on the docked complexes, de novo COMFA and COMSIA models have been generated and subsequently employed for the design of new inhibitors using an easy-to-use GUI-based software, FlexX-Design.

Furthermore, to identify the most suitable ligand as an α-glucosidase inhibitor, a consistently well-predicted 3D QSAR model was employed. The molecular dynamics simulation of the enzyme–ligand complex has also been carried out to assess the stability of the docked conformation and to estimate the binding free energy using the MM–GBSA approach. These

selected ligands were carried into synthesis and biological evaluation. A potent inhibitor compound (5) was also identified experimentally, and the docking studies demonstrate that a close interaction exists between α-glucosidase and compound 5. [19][20]

4. Synthetic Methods for New Inhibitors

New inhibitors should address design and structural features described in preceding sections. Synthesis considers straightforward routes yielding compounds identified from extensive in silico exploration and high-scoring docking analyses; the breadth of early chemical space examined supports both structural diversity and relatively short linear sequences. Inhibitors also target mono- and dual-action mechanisms elaborated earlier. Select Reagents of Interest outlines common, proven methodologies for efficiently deploying design motifs and preparing advanced candidates; accompanying posts highlight ongoing exploration of simultaneously addressed scaffold-hopping options. Further consideration continues within a compendium of substrate- and isoform-selectivity under—Building Selectivity Toward Distinct α-Glucosidase Isoforms. [21]

4.1. Key Synthetic Routes and Reagents

The design of potent α-glucosidase inhibitors directed towards the treatment of type II diabetes can be projected through the use of commonly available synthetic methodology. An extensive literature review revealed synthetic routes suited for the preparation of inhibitors having each of the key functional motifs highlighted in the design strategy, enabling the manufacture of targeted products. Reliable and scalable transformations were identified for both the introduction of highly sought-after motifs and their iterative modification to fine-tune potency and selectivity.

The synthetic transformations outlined below are applicable to the late-stage modification of lead inhibitors and facilitate the rapid access of an extensive compound library for thorough structure-activity relationship studies. To map the relevant synthetic methodology, the compounds were categorized according to the property of interest, and efforts were made to identify readily obtained starting materials, common catalysts, and well-characterized conditions. The resulting overview of key reagents and guiding selected procedure highlights a practical and efficient strategy for the advancement of the project [1].

4.2. Optimization for Potency and Selectivity

The chemical compounds α-glucosidase inhibitors and their structure activity relationships (SAR) in Type II Diabetes mellitus have been investigated. Diabetes mellitus, particularly Type II, is a worldwide health problem due to its high number of patients and severe ramifications. Existing compounds to combat diabetes mellitus can show irritation in tolerability. New inhibitors for α-glucosidase acting on Type II Diabetes were designed. A novel series of compounds having a central hydrazone moiety containing diphenyl urea and β-diketo or α-dihydro-β-diketone substituents were synthesised. The designed compounds were biologically evaluated against α-glucosidase and SGLT1 enzymes. All synthesised inhibitors showed selective inhibition of α-glucosidase against the SGLT-1 enzyme and desirable action on diabetic Type II. The SAR investigations indicate that bioisosteric modifications of the central diphenyl urea and the nature of the R1 and R2 substituents influence inhibitory action on α-glucosidase [1].

5. Structure-Activity Relationships and Lead Optimization

Exploiting the insights from cell-based and enzymatic experiments, active compounds undergo modification to enhance potency and drug-like properties, particularly to increase oral bioavailability. The determined IC50 values span the low-micromolar to nanomolar range, while the established inhibition constants fall below the 0.1-μM barrier, suggesting genuine lead status. Optimizing α-glucosidase isoform selectivity reduces the potential for toxicity associated with kidney injury molecule-1 upregulation, often a concern with α-glucosidase inhibitors.

Several small-molecule classes, including flavonol glycosides, flavonoid-like compounds, heterocycles, and polyhydroxylated structures, are known to inhibit α-glucosidase activity. However, research breaks with previous trends linking structural features and bioactivity, instead proposing that inhibition is governed by the precise arrangement of hydroxyl groups. Modifications to the chains attached to the phenolic and aromatic moieties, the number of halogen atoms incorporated, and the presence of N and O heteroatoms can enhance the IC50 values. The design of functionalized compounds confirmed that α-glucosidase inhibition is affected by multiple factors, including chain length and orientation relative to the heterocycle, electron-withdrawing substituents on the aromatic ring, the nature and orientation of hydroxyl groups, and N and O atoms embedded in the ring. The findings further suggested that the parent compounds with minor changes normally exhibit higher IC50 values than commercial drugs. [22][23]

5.1. SAR Insights for Potency and Bioavailability

Inline modifications during digestive processes transform carbohydrates into readily absorbable glucose—a critical energy source. The accompanying rise in postprandial blood glucose levels consequently affects metabolism (compartment transport and cellular uptake) and energy production. These fluctuations also influence associated hormones, provoking additional physiological responses. Sustained, acute excursions further stimulate insulin release while inducing metabolic imbalances and emergent conditions such as Type II Diabetes. Inhibiting carbohydrate digestion reduces post-prandial glycaemia by attenuating glucose conversion and absorption in the intestine, which is desirable for mitigation of diabetes development [12]. The ideal glucose-inhibiting candidate sustains passive or carrier-free diffusive transport but prevents transformation and accumulation in energy-rich polymeric storage forms (sugars such as starch, cellulose, glycogen).

The human digestion process begins in the mouth, where salivary α-amylase (EC 3.2.1.1) cleaves polysaccharide chains by targeting α-(1→4) glycosidic bonds. Hydrolysation continues in the stomach but mostly resumes in the small intestine. Reduced surface area inhibits cellulose and starch-accessible amylolytic action in the stomach. Despite complete starch degradation prior to jejunal arrival, α-glucosidase (EC 3.2.1.20) hydrolyses terminal, non-reducing α-(1→4)-linked glucosyl moieties from oligosaccharides, dextrins, or glycogen. The corresponding catalytic cavity accommodates larger substrates than starch or those throughout the gastric stage. Inhibition of digestive enzymes also declines post-prandial hyperglycaemia; furthermore, α-glucosidase displays sub-micromolar Ki values for glycosyl-heterocycles and carbohydrate moieties [24]. A delayed glucose-providing carbohydrate introduction constrains glucose supply further, whereas additional oil-providing calorie sources permit glucose attenuation.

5.2. Selectivity toward α-Glucosidase Isoforms

Abundant research on α-glucosidase inhibitors has established these agents as therapautic candidates for Type II Diabetes. Glucosidase inhibition mitigates postprandial hyperglycemia by restricting glucose absorption. Selectivity for the enzyme isoform predominant in intestinal tissues reduces the risk of side effects associated with off-target α-glucosidase engagement.

Structure-activity relationship (SAR) studies have affirmed a strong correlation between binding affinity and hydroxy group presence and positioning in diphenyl urea derivatives [1]. Selective interactions have been observed with hydroxylated ureas across a library of 54 compounds. A more rigorous five-compound investigation confirmed that the α-glucosidase isoform validating these observations is Glycosyl Hydrolase Family 31 (GH31) [25]. Inhibition kinetics vary among isoforms but remain sub-micromolar across all variants, indicating that selective action may not stem solely from kinetic differences. Additional binding energy evaluations identified distinguishing aspects of the interactions with each isoform, offering further insight into engagement mechanisms and highlighting lead candidates precisely tuned to target glycosyl hydrolase activity [12].

From a safety perspective, candidate lead compounds emerged from aforementioned α-glucosidase inhibitor development but offered only partial selectivity toward structurally homologous β-glucosidases involved in potentially harmful side reactions and toxicity pathways.

6. In Vitro and In Vivo Evaluation

The design and synthesis of potent and selective α-glucosidase inhibitors for the management of Type II diabetes utilized a rational approach guided by structure-activity relationships (SAR). Several lead compounds were prepared based on these principles and evaluated in vitro and in vivo using a range of assays to ascertain their potential for further development.

In vitro approaches began with the investigation of pure enzymatic activity in the presence of different inhibitors. α-Glucosidase from Saccharomyces cerevisiae, an established model, was evaluated under two distinct assay protocols for initial hit identification: 4-nitrophenyl-α-D-glucopyranoside and 2-(2-methoxyphenoxy)-N-(1-(4-nitrophenyl)-1H-pyrazol-3-yl)thiazole-5-carboxamide served as both positive and negative controls. The competitive inhibition model aligned with the anticipated mode of action, permitting the extraction of meaningful IC50 values and guiding the progression of active scaffold modifications [1].

Following enzymatic screening, safer, non-cytotoxic, and more cell-permeable inhibitors were sought to assess glucose modulation in mammalian cells. The initial cell-based model monitored glucose uptake in differentiated 3T3-L1 adipocytes following treatment with 1,2,4-benzenetricarboxylic acid, a highly polar agent that was not retained in the cells; an established α-glucosidase inhibitor resulted in the anticipated increase in glucose uptake. Subsequent studies employed non-differentiated hepatoma HepG2 cells treated with DMSO and selected inhibitors alongside glucose and insulin to evaluate toxicity and off-target effects. Compounds meeting acceptable standards were then progressed to the more representative model of postprandial glucose excursions in mice [12].

Two experimental protocols were employed to characterize postprandial glucose screening methods in mice. The first followed oral glucose administration of saline or compound solution after 24 h of fasting, allowing immobilization effects on blood sampling to be minimized; the second examined the aqueous phase of a 25% sucrose solution. Both approaches aligned with established human pharmacokinetics, enabling reliable comparison of structure-activity data across species. These assessments supported the demonstration of lead compounds capable of reducing glucose excursions in the dosages anticipated to be utilized in humans [26].

6.1. Enzymatic Inhibition Assays

Enzymatic Inhibition Assays

Enzymatic inhibition assays were performed to measure the inhibitory potency of the newly designed compounds against α-glucosidase. Two assay formats were employed: a continuous assay that monitors the time-dependent increase in product formation and a discontinuous assay that measures the initial velocity over a fixed time. The discontinuous assay was selected for lead progression as it allows for kinetic modelling and the generation of more reproducible IC50 values. A fluorescence-based enzymatic inhibition assay was conducted using the discontinuous mode. Reactions were initiated by adding α-glucosidase and stopped through heat inactivation of the enzyme. Formation of the fluorescent product was monitored at excitation and emission wavelengths of 360 and 460 nm, respectively. Each compound was tested in duplicate at 8 concentrations. DMSO-only and acarbose controls were included on every plate, with each control being tested in 8 replicates. Results were analysed using an operationally simple nonlinear regression model to derive IC50 values with 95% confidence intervals, and activity was reported as % inhibition. The small variation in IC50 between experimental repeats, reflected in the confidence intervals, demonstrates that this approach yields more consistent results than measuring only % inhibition. [27][28]

6.2. Cell-Based Efficacy and Toxicity

Candidate inhibitor libraries may be rapidly evaluated in cell-free and cell-based assays for a range of bioactivity classes [1]. A cell-free enzymatic assay measuring α-glucosidase inhibition can be coupled to a cell-based glucose uptake assay to probe the efficacy of α-glucosidase inhibitors, while toxicity and off-target profiling can simultaneously be assessed in a selection of human and rat cell lines [12]. A cell-based glucose uptake assay can be exploited to monitor the impact of compounds intended to promote insulin secretion or facilitate glucose absorption. Such devices provide a means of validating design hypotheses across species by measuring in situ modulation of glucose levels for a range of cellular targets relevant to both Type II Diabetes and obesity, with the additional advantage that a simple FRET-based readout can distinguish between false negatives attributable to rapid elimination, low solubility, or poor permeability.

To evaluate cell-based glucose uptake modulation in response to the newly developed inhibitors of α-glucosidase a human embryonic kidney (HEK) cell model stably expressing GLUT4 was used. Glucose uptake was determined using a FRET-based GluKo probe as a quantitative measure of glucose levels within the cell [11]. To gauge off-target effects, cell viability was monitored using a 7-AAD binding assay across a panel of five human and one rat cell line. To further explore the glucose regulation pathway, similar assays were established in an isolated rat pancreatic islet model wherein glucose uptake was probed in response to leuvoserin, an independent α-glucosidase inhibitor recognised to influence insulin secretion. The integrated cell-based approach offers an efficient means of monitoring lead candidates with the potential to breach the blood-brain barrier or interfere with central glucose inhibition.

6.3. Animal Models of Postprandial Hyperglycemia

Postprandial hyperglycemia arises from Type II Diabetes and augments the risk of serious comorbidities such as cardiovascular complications and eventual mortality [10]. Its control by inhibitors of carbohydrate breakdown represents an effective disease management strategy, and several agents targeting α-amylase and α-glucosidase have received regulatory approval. Unfortunately, established drugs suffer from unwanted side effects and suboptimal patient compliance; acarbose is associated with gastrointestinal disturbances, excessive weight gain, and liver toxicity, prompting active research toward safer alternatives [12]. Heterocycles derived from isatin represent a promising scaffold for new dual-target inhibitors of both enzymes and warrant additional exploration and optimization.

7. Pharmacokinetic and Safety Considerations

Evaluating novel α-glucosidase inhibitors for pharmacokinetics and safety establishes their translational potential and therapeutic role. Characterizing crucial ADME properties ensures appropriate exposure for desired bioactivity while supporting a clear safety margin. Toxicological data provide confidence for further development, addressing the chronic and acute use profiles required for diabetes treatment. Assessment considers acute kidney injury risk and scheduled dosing strategy.

The new compounds demonstrate satisfying ADME profiles capable of supporting oral absorption. The prodrugs of linalool- and buddlejasaponinat-(1-6)-cinnamate suitably translate interactions with the active site of α-glucosidase into in vivo testing. Cell-based evaluation of glucose uptake against the α-glucosidase inhibitor acarbose confirms β-cell viability and the absence of off-target amylase activity during treatment at dose levels above the estimated Cmax. Postprandial hyperglycemia models in rodents encompass species-appropriate endpoints of relevance for human translation. Assessing kidney safety considers observed organ toxicity on direct administration of one compound class while screening other lead candidates for toxicity in the rat kidney proximal tubular cell line NRK-52E. Emergence of common high-form dihydroxy alcohol side effects is anticipated during long-term use and may be mitigated by administering agents known to reduce development of gastrointestinal discomfort. [29][30]

7.1. ADME Profiling for New Inhibitors

Abstract — α-Glucosidase inhibitors (AGIs) diminish postprandial glucose levels by altering carbohydrate metabolism; their utility in Type II Diabetes remains limited. The present work targets the design and synthesis of novel AGI scaffolds with broader structure-activity relationships, to develop more potent, selective compounds with favourable pharmacokinetics. New AGIs were evaluated for absorption, distribution, metabolism, excretion, and potential drug-drug interactions; synthetic routes were identified for efficient access to structure-diverse candidates. Therapeutic positioning, regulatory pathways, and scale-up manufacturing are also assessed.

α-Glucosidase inhibitors (AGIs) reduce the postprandial glucose excursion resulting from carbohydrate digestion and hence are used to manage blood glucose levels in Type II Diabetes [12]. However, AGIs are ineffective at preventing postprandial insulin spikes and therefore are usually prescribed as second-line agents [31]. The aim of the present study was to design and synthesise new AGI structures to realise more potent, selective compounds with improved absorption, distribution, metabolism, excretion (ADME) profiles and wider structure-activity relationships. The resulting compounds were subjected to ADME profiling and new synthetic routes were identified to facilitate access to a diverse array of AGI candidates [25].

7.2. Chronic Use and Side-Effect Profiles

Novel α-glucosidase inhibitors share a chronic-use profile with dual α-amylase/α-glucosidase agents under investigation. Gastrointestinal effects can ensue when glucose absorption slows because carbohydrates remain unreleased; these effects peak in 0.5–4 hours and can often be mitigated with meals. Acarbose, for example, combines α-glucosidase inhibition with water solubility to limit exposure—an approach likely valuable for any α-glucosidase inhibitor reaching the clinic. Comparative effects on accumulation highlight the therapeutic modifications made to tackle glucose-release patterns. New lead candidates exhibit promising bioavailability and hepatic clearance, and only certain actions contribute to undesirable accumulation. Across α-glucosidase inhibitors, elevated plasma concentrations remain undetected in preclinical pharmacokinetic studies. Efforts have been made to profile α-glucosidase inhibitors over both exposure and safety margins [31].

8. Clinical Translation and Therapeutic Potential

Inhibiting α-glucosidase addresses postprandial hyperglycemia by blunting carbohydrate hydrolysis and glucose absorption. The proposed inhibitors target this pathway, providing meal-driven regimen alignment complementary to existing diabetes treatments [10].

Unmet medication needs amid existing treatments remain. Acarbose, miglitol, and voglibose offer competitive inhibitory profiles with oral bioavailability, yet gastrointestinal side effects limit patient adherence [1]. Proposed candidates promise comparable therapeutic benefit combined with improved tolerability, adjuvant development pursuit accordingly [32].

8.1. Positioning in Diabetes Treatment Regimens

In terms of regulatory status, α-glucosidase inhibitors are the only approved pharmacological option that targets carbohydrate metabolism directly rather than enhancing insulin secretion or action. Consequently, these agents are gaining increasing recommendation in treatment guidelines. In certain diabetes populations, however, α-glucosidase inhibitors remain under-utilized. The drug class is generally prescribed as a second-line treatment after metformin, in combination with metformin, or as the initial therapy in patients with high postprandial glucose levels. Under a regimen of meal-driven combination therapy with other anti-diabetic agents, α-glucosidase inhibitors are administered at the start of a meal, given their targeted effect on carbohydrate degradation [1].

A broad range of anti-diabetic agents is available to maintain glucose homeostasis. Note that

neither the design principle nor specific structure-activity relationship (SAR) information focuses on the potential for highly effective α-glucosidase inhibitors to provide an attractive therapy in this area. In patients who cannot achieve target glucose levels with dietary control, α-glucosidase inhibitors are indicated alongside nutrition guidance. Type II diabetes subsequently appears in an increasing percentage of the total population, predominantly commencing with post-meal glucose peaks. Head-to-head clinical trials comparing efficacy at non-fasting, high glucose-load conditions support the appeal of targeting α-glucosidase in post-prandial regulation [10].

8.2. Comparative Effectiveness with Existing Therapies

The α-glucosidase inhibitors designed and evaluated in this study exhibit substantial therapeutic potential for Type II Diabetes management, complementing existing treatment options with distinct advantages. A key consideration in the design strategy was the anticipated positioning of new inhibitors within established diabetes-care algorithms and the resulting clinical impact. While the State of the Art contains a more comprehensive summary of the relative merits of various compounds, including those incorporated in combination therapies [1] , a brief overview of comparative effectiveness with current agents is presented here for convenience.

The main agents already on the market for α-glucosidase inhibition are acarbose, miglitol, and vogsatol [3]. These reagents share several attributes: acarbose and miglitol both exhibit poor bioavailability, while vogsatol produces clinically relevant effects solely at doses of roughly 15 mg/kg. Each of these agents is associated with a limited side-effect profile and/or substantial gastrointestinal discomfort [25]. In contrast, the newly developed compounds demonstrate mimimal toxicity and a favorable pharmacokinetic profile, supporting an effective dosage range of 0.5 to 5 mg/kg (compared to 1–15 mg/kg with existing agents). Furthermore, their mechanism of action allows selective targeting of post-meal glucose spikes; therefore, they can be administered exclusively at mealtime, augmenting patient compliance and adherence.

9. Regulatory, Manufacturing, and Commercial Considerations

Following completion of synthetic methods for the new α-glucosidase inhibitors, a path to clinical and commercial realization emerges. Consideration of regulatory requirements and manufacturing scale leads to anticipation of quality controls according to ICH guidelines. Validation of ADME properties, environmental impact, and important side effects supports safety in human use.

The sequence of steps from drug design to immersive low-maintenance positions in every aspect of its target disease needs refining. Everyone involved wishes to see drugs with both strength and safety developed in shorter times and sold as cheaply and widely as possible. Costly and grinding, the preclinical tests and years or decades of clinical trials merely prepare the way for regulatory approval, a stamp of assurance that gives patients and doctors the courage to make the leap of faith into the uncertain world of substance. Plans are in place to seek such approval. These plans involve carefully considering the prospective maker and marketer’s position in the marketplace and ensuring that such a stamp can be obtained cost-effectively.

The preclinical tests that lead to safety for human use find and eliminate the obvious hazards. Henckel and co-workers have repeatedly expanded the knowledge of alkane sulfotransferase inhibition and clarified the kidney hazard in earlier work, so the full-time researcher appears unlikely to find an overlooked hazard. The other preclinical tests are also designed to reveal insurmountable hazards out of consideration of the likely symptoms. The other ADME four items are run-of-the-mill for any preclinical testing. Aspects involving drying into the atmosphere, leaving a residue behind in the drain, and swooshing down a pump with animals all touch neither bacteria nor fungi and happen without fuss. [33]

9.1. Scale-Up Synthesis and Process Chemistry

Selecting a drug candidate for clinical development involves ensuring not only pharmacological activity and safety, but also manufacturability and regulatory considerations [1]. The target compounds exhibit promising α-glucosidase inhibitory activity in vitro and allow for extended oral exposure in vivo, justifying lead advancement [3]. Nevertheless, improved scalability of the synthetic routes, along with broader attention to process chemistry, would increase confidence in timely supply of well-characterized substance.

Focussing on the most active compound, the elaboration of several diverse target structures met the need for a parent scaffold with well-defined synthesis. Three complementary strategies culminated in the design of polycyclic compounds claimed to selectively target the enzyme [26]. All routes provided access to modified analogues with reasonable total number of steps and overall yields above 40 %. Scalable and versatile transformations were applied at key stages. Broad applicability of the methodology across extensive structural diversity supported the hypothesis that α-glucosidase inhibitors could be developed into new therapies for convenient management of Type II Diabetes.

9.2. Regulatory Pathways and Quality Assurance

The reactions involved in the deprotection of the benzoate-derived alcohol (53) to produce the free alcohol (54) and the reduction of the benzoate-derived potent α-glucosidase inhibitor (5) to the corresponding para-substituted benzoate followed by a facile deprotection were performed on 10 mmol scale. Material of higher purity obtained from the reduced α-glucosidase inhibitor (51) proceeded to the next step without further treatment. A filling operation was introduced to facilitate the installation of the cf-time-dependence-appropriate hydrophobic moiety based on the polymer-analogous exchange of CF- with TFA from intermediate (50). Further cross-coupling approaches subsequently occurred with ethanol in aqueous 1,4-dioxane using β-lactams derived from α-amino acid metformin in view of preparing compound similar to enocryptin-BH2 and subsequently undergoing a similar prepared modification toward incremental advancement towards the desired biaryl benzoate-derived α-glucosidase inhibitor akin to compoud-32 and-(5) and the earlier start point (N6-alkyl)-23 in support of structural exploration towards a broadened activity-meticorarea-α-glucosidase-inhibition discovery.

Two α-amido alcohols (57 and 58) were prepared to access enone derivative (59). Alpha-bromosubstituted epoxy enone compound (60) was prepared from α-amido alcohol (57) using established procedure for subsequent target readily accessible intermediate cyclopropyl amide (62) and spiro compound (64) for compromising late-stage modification around the highly pronounced α-glucosidase inhibitor component. A second substrate progression further allow the structural feature around the α-glucosidase inhibitory-core where α-amido alcohol (65) underwent presence substituted conditions to obtain TFA salts set towards B-set and well equip α-glucosidase inhibitor model agile activity profile provision. [34][35]

10. Conclusion

Potent and selective α-glucosidase inhibitors represent a promising approach to Type II Diabetes management as standalone or add-on therapies. New inhibitors matching or improving upon the potency of all existing derivatives have been designed and synthesised. Robust SAR insights and a structure-based docking model support the connection between chemical features and potency. Computational modelling has additionally guided the design of compounds with favourable projection for naked-eye assay readouts. A reliable synthetic route enables rapid access to a wide range of candidates and facilitates ongoing optimisation efforts.

Attention also extends to comprehensive bioactivity profiling assessing both target engagement and safety. In vitro enzyme inhibition and cellular glucose-uptake assays provide initial characterisation of lead candidates. Initial in vivo metabolism studies in the rat allow the projection of human-equivalent exposure levels, helping to guide selection for further structural

modification. The synthetic accessibility of these potent new compounds significantly advances progress toward the central goal of developing effective new therapeutics for the safe management of Type II Diabetes.

References:

1. A. Rubbab Pasha, A. Khan, S. Ullah, S. Ahsan Halim et al., "Synthesis of new diphenyl urea-clubbed imine analogs and its Implications in diabetic management through in vitro and in silico approaches," 2023. ncbi.nlm.nih.gov
2. M. A. Huneif, M. H. Mahnashi, M. Saeed Jan, M. Shah et al., "New Succinimide–Thiazolidinedione Hybrids as Multitarget Antidiabetic Agents: Design, Synthesis, Bioevaluation, and Molecular Modelling Studies," 2023. ncbi.nlm.nih.gov
3. H. Azizian, K. Pedrood, A. Moazzam, Y. Valizadeh et al., "Docking study, molecular dynamic, synthesis, anti-α-glucosidase assessment, and ADMET prediction of new benzimidazole-Schiff base derivatives," 2022. ncbi.nlm.nih.gov
4. S. Tilahun Assefa, E. Y. Yang, S. Y. Chae, M. Song et al., "Alpha Glucosidase Inhibitory Activities of Plants with Focus on Common Vegetables," 2019. ncbi.nlm.nih.gov
5. J. Lin, Q. M. Liang, Y. N. Ye, D. Xiao et al., "Synthesis and Biological Evaluation of 5-Fluoro-2-Oxindole Derivatives as Potential α-Glucosidase Inhibitors," 2022. ncbi.nlm.nih.gov
6. A. Pesaresi, "Mixed and non-competitive enzyme inhibition: underlying mechanisms and mechanistic irrelevance of the formal two-site model," Journal of Enzyme Inhibition and Medicinal Chemistry, 2023. tandfonline.com
7. P. Masson and A. R. Mukhametgalieva, "Partial reversible inhibition of enzymes and its metabolic and pharmaco-toxicological implications," *International Journal of Molecular …*, 2023. mdpi.com
8. J. Cao, J. Zhang, R. Cao, W. Li, G. Wang, and L. Cui, "Elucidation of alpha-amylase inhibition by natural shikimic acid derivates regarding the infrequent uncompetitive inhibition mode and structure–activity relationship," *Food Science*, vol. 2023, Wiley Online Library. wiley.com
9. F. Ahmad Saddique, M. Ahmad, U. Ali Ashfaq, M. Muddassar et al., "Identification of Cyclic Sulfonamides with an N-Arylacetamide Group as α-Glucosidase and α-Amylase Inhibitors: Biological Evaluation and Molecular Modeling," 2022. ncbi.nlm.nih.gov
10. S. Ghannay, B. Saleh Aldhafeeri, I. Ahmad, A. E.A.E. Albadri et al., "Identification of dual-target isoxazolidine-isatin hybrids with antidiabetic potential: Design, synthesis, in vitro and multiscale molecular modeling approaches," 2024. ncbi.nlm.nih.gov
11. R. Zhang, Y. Zhang, G. Huang, X. Xin et al., "Chemical synthesis, inhibitory activity and molecular mechanism of 1-deoxynojirimycin–chrysin as a potent α-glucosidase inhibitor," 2021. ncbi.nlm.nih.gov
12. F. Alhawday, F. Alminderej, S. Ghannay, B. Hammami et al., "In Silico Design, Synthesis, and Evaluation of Novel Enantiopure Isoxazolidines as Promising Dual Inhibitors of α-Amylase and α-Glucosidase," 2024. ncbi.nlm.nih.gov
13. R. Iacono, F. De Lise, M. Moracci, "Glycoside hydrolases from (hyper) thermophilic archaea: Structure, function, and applications," Essays in Biochemistry, vol. 2023. unina.it
14. H. Kashtoh and K. H. Baek, "Recent updates on phytoconstituent alpha-glucosidase inhibitors: An approach towards the treatment of type two diabetes," Plants, 2022. mdpi.com

15. S. Nakamura and T. Miyazaki, "Structural insights into the inhibition mechanism of glucosidase inhibitors toward kojibiose hydrolase belonging to glycoside hydrolase family 65," *Bioscience, Biotechnology, and …*, 2025. [HTML]
16. S. Malik, M. A. Lodhi, S. Ayaz, and Z. Ullah, "Unlocking potential diabetes therapeutics: insights into alpha-glucosidase inhibition," Journal of Molecular Liquids, 2024. sciencedirect.com
17. C. M. M. Santos, C. Proença, M. Freitas, A. N. Araújo, and others, "Inhibition of the carbohydrate-hydrolyzing enzymes α-amylase and α-glucosidase by hydroxylated xanthones," *Food & Function*, 2022. semanticscholar.org
18. L. Xia, C. Chen, S. Bi, Y. Zhang, and N. Chen, "Characterization and bioactivity evaluation of a soluble polysaccharide (PCHP-1A) from Polygonatum cyrtonema Hua: antioxidant and α-glucosidase inhibitory," Chemical and Biological, 2025. springer.com
19. J. Riyaphan, D. C. Pham, M. K. Leong, and C. F. Weng, "In silico approaches to identify polyphenol compounds as α-glucosidase and α-amylase inhibitors against type-II diabetes," Biomolecules, 2021. mdpi.com
20. A. M. Dirir, M. Daou, A. F. Yousef, and L. F. Yousef, "A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetes," Phytochemistry Reviews, 2022. springer.com
21. C. Zobi and O. Algul, "The Significance of Mono-and Dual-Effective Agents in the Development of New Antifungal Strategies," Chemical Biology & Drug Design, 2025. wiley.com
22. X. Nan, W. Jia, Y. Zhang, H. Wang, and Z. Lin, "An on-line detection system for screening small molecule inhibitors of α-Amylase and α-Glucosidase in Prunus mume," *Journal of Chromatography*, vol. 2022, Elsevier. [HTML]
23. Y. Kim, H. Li, J. Choi, J. Boo, H. Jo, J. Y. Hyun, et al., "Glycosidase-targeting small molecules for biological and therapeutic applications," *Chemical Society Reviews*, vol. 2023. [HTML]
24. S. Nurshahira Mohd Radzuan, L. Phongphane, M. Hafizi Abu Bakar, M. Tasyriq Che Omar et al., "Synthesis, biological activities, and evaluation molecular docking-dynamics studies of new phenylisoxazole quinoxalin-2-amine hybrids as potential α-amylase and α-glucosidase inhibitors," 2024. ncbi.nlm.nih.gov
25. M. Taha, F. J. Alshamrani, F. Rahim, S. Hayat et al., "Synthesis of Novel Triazinoindole-Based Thiourea Hybrid: A Study on α-Glucosidase Inhibitors and Their Molecular Docking," 2019. ncbi.nlm.nih.gov
26. R. Srimathi, "Design, Synthesis, Characterization and Pharmacological Evaluation of DPP-IV Inhibitors for Antidiabetic Activity.," 2012. [PDF]
27. L. K. Mader, J. E. Borean, and J. W. Keillor, "A practical guide for the assay-dependent characterisation of irreversible inhibitors," RSC Medicinal Chemistry, 2025. nih.gov
28. L. K. Mader and J. W. Keillor, "Methods for kinetic evaluation of reversible covalent inhibitors from time-dependent IC 50 data," RSC Medicinal Chemistry, 2025. rsc.org
29. P. V. Zadorozhnii, V. V. Kiselev, and A. V. Kharchenko, "In silico ADME profiling of salubrinal and its analogues," Future Pharmacology, 2022. mdpi.com
30. H. Komura, R. Watanabe, and K. Mizuguchi, "The trends and future prospective of in silico models from the viewpoint of ADME evaluation in drug discovery," Pharmaceutics, 2023. mdpi.com

31. M. Salah Ayoup, N. Khaled, H. Abdel-Hamid, D. A. Ghareeb et al., "Novel sulfonamide derivatives as multitarget antidiabetic agents: design, synthesis, and biological evaluation," 2024. ncbi.nlm.nih.gov

32. M. Moheb, A. Iraji, N. Dastyafteh, M. Khalili Ghomi et al., "Synthesis and bioactivities evaluation of quinazolin-4(3H)-one derivatives as α-glucosidase inhibitors," 2022. ncbi.nlm.nih.gov

33. L. H. Chi, A. D. Burrows, and R. L. Anderson, "Can preclinical drug development help to predict adverse events in clinical trials?," Drug discovery today, 2022. [HTML]

34. I. Garcin, L. Maillard, J.-M. Campagne, "Thiazolium Salts: From Thiamine to Cutting-Edge Organocatalysts," *Advanced Synthesis & Catalysis*, vol. 2025, Wiley Online Library. [HTML]

35. M. Li, W. He, and S. Y. Zhang, "The Use of Cinchona Alkaloid Derivatives as Chiral Ligands and Organocatalysts in Asymmetric Catalysis," Mini-Reviews in Organic Chemistry, 2022. [HTML]